BRPI0717098B8 - análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação - Google Patents
análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparaçãoInfo
- Publication number
- BRPI0717098B8 BRPI0717098B8 BRPI0717098A BRPI0717098A BRPI0717098B8 BR PI0717098 B8 BRPI0717098 B8 BR PI0717098B8 BR PI0717098 A BRPI0717098 A BR PI0717098A BR PI0717098 A BRPI0717098 A BR PI0717098A BR PI0717098 B8 BRPI0717098 B8 BR PI0717098B8
- Authority
- BR
- Brazil
- Prior art keywords
- insulin analogues
- protease
- preparation
- pharmaceutical composition
- human insulin
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 108091005804 Peptidases Proteins 0.000 title abstract 3
- 239000004365 Protease Substances 0.000 title abstract 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 8
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06121113.2 | 2006-09-22 | ||
| EP061211132 | 2006-09-22 | ||
| EP06121113 | 2006-09-22 | ||
| PCT/EP2007/059990 WO2008034881A1 (en) | 2006-09-22 | 2007-09-20 | Protease resistant insulin analogues |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0717098A2 BRPI0717098A2 (pt) | 2013-10-08 |
| BRPI0717098B1 BRPI0717098B1 (pt) | 2018-08-07 |
| BRPI0717098B8 true BRPI0717098B8 (pt) | 2021-05-25 |
Family
ID=38754488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0717098A BRPI0717098B8 (pt) | 2006-09-22 | 2007-09-20 | análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9018161B2 (enExample) |
| EP (2) | EP2404934A1 (enExample) |
| JP (2) | JP5864834B2 (enExample) |
| KR (2) | KR101729986B1 (enExample) |
| CN (1) | CN101541830A (enExample) |
| AU (1) | AU2007298919C1 (enExample) |
| BR (1) | BRPI0717098B8 (enExample) |
| CA (1) | CA2663074A1 (enExample) |
| DK (1) | DK2074141T3 (enExample) |
| ES (1) | ES2601839T3 (enExample) |
| HU (1) | HUE029512T2 (enExample) |
| IL (1) | IL197609A (enExample) |
| MX (1) | MX2009002999A (enExample) |
| NO (1) | NO20091563L (enExample) |
| PL (1) | PL2074141T3 (enExample) |
| PT (1) | PT2074141T (enExample) |
| RU (1) | RU2524150C2 (enExample) |
| TW (1) | TW200829600A (enExample) |
| WO (1) | WO2008034881A1 (enExample) |
| ZA (1) | ZA200901838B (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1969004B1 (en) | 2005-12-28 | 2011-08-10 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| CN101541830A (zh) | 2006-09-22 | 2009-09-23 | 诺沃-诺迪斯克有限公司 | 蛋白酶抗性的胰岛素类似物 |
| WO2008132224A2 (en) | 2007-04-30 | 2008-11-06 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
| EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| AU2008257505B2 (en) | 2007-06-01 | 2013-05-16 | Novo Nordisk A/S | Stable non-aqueous pharmaceutical compositions |
| JP5552046B2 (ja) | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | インスリン誘導体を含有する薬学的製剤 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| RU2524423C2 (ru) | 2008-01-09 | 2014-07-27 | Санофи-Авентис Дойчланд Гмбх | Новые производные инсулина с чрезвычайно замедленным профилем время/действие |
| CN101970477B (zh) * | 2008-03-14 | 2014-12-31 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定的胰岛素类似物 |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| WO2009133099A2 (en) * | 2008-04-28 | 2009-11-05 | Novo Nordisk A/S | Insulin precursors for diabetes treatment |
| PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| CN102202683A (zh) | 2008-10-30 | 2011-09-28 | 诺沃-诺迪斯克有限公司 | 用少于每日一次的注射频率注射胰岛素来治疗糖尿病 |
| EP2376531A1 (en) * | 2008-12-09 | 2011-10-19 | Novo Nordisk A/S | Novel insulin analogues |
| ES2543705T3 (es) | 2009-06-26 | 2015-08-21 | Novo Nordisk A/S | Preparación que contiene insulina, nicotinamida y arginina |
| EP2448962B1 (en) | 2009-06-30 | 2016-10-19 | Novo Nordisk A/S | Insulin derivatives |
| PH12011502708B1 (en) | 2009-07-06 | 2017-11-10 | Sanofi Aventis Deutschland | Insulin preparations containing methionine |
| EP2451471A1 (de) * | 2009-07-06 | 2012-05-16 | Sanofi-Aventis Deutschland GmbH | Langsamwirkende insulinzubereitungen |
| EP2477644A1 (en) | 2009-09-16 | 2012-07-25 | Novo Nordisk A/S | Stable non-aqueous liquid pharmaceutical compositions comprising an insulin |
| CN102665676B (zh) | 2009-11-02 | 2015-04-01 | 诺沃-诺迪斯克有限公司 | 非共价结合的白蛋白和酰化胰岛素的药物溶液 |
| JP5832439B2 (ja) | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| BR112012016853A2 (pt) * | 2010-01-12 | 2017-10-17 | Novo Nordisk As | "composições farmacêuticas para administração oral de peptídeos de insulina". |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| EP2585484A1 (en) | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Insulin analogues containing additional disulfide bonds |
| CA2802510A1 (en) | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
| EP2585483A1 (en) | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Human insulin containing additional disulfide bonds |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| JP2013540771A (ja) | 2010-10-15 | 2013-11-07 | ノヴォ ノルディスク アー／エス | 新規ｎ末端修飾インスリン誘導体 |
| DK2632478T3 (da) | 2010-10-27 | 2019-10-07 | Novo Nordisk As | Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller |
| WO2012080320A1 (en) | 2010-12-14 | 2012-06-21 | Novo Nordisk A/S | Fast-acting insulin in combination with long-acting insulin |
| KR20140030125A (ko) | 2010-12-14 | 2014-03-11 | 노보 노르디스크 에이/에스 | 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제 |
| CN103458873B (zh) | 2011-04-14 | 2016-04-13 | 诺沃—诺迪斯克有限公司 | 用于口服肽递送的脂肪酸酰化的氨基酸 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| EP2720711A1 (en) | 2011-06-15 | 2014-04-23 | Novo Nordisk A/S | Multi substituted insulins |
| JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ２型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013059213A1 (en) * | 2011-10-18 | 2013-04-25 | Amidebio, Llc | Chemically and thermodynamically stable insulin analogues and improved methods for their production |
| EP2836508B1 (en) | 2012-04-11 | 2016-06-29 | Novo Nordisk A/S | Insulin formulations |
| WO2013186138A1 (en) | 2012-06-14 | 2013-12-19 | Novo Nordisk A/S | Preparation comprising insulin, nicotinamide and arginine |
| JP6285447B2 (ja) | 2012-10-17 | 2018-02-28 | ノヴォ ノルディスク アー／エス | 経口ペプチド送達用の脂肪酸アシル化ｄ−アミノ酸 |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| PL2981310T3 (pl) | 2013-04-05 | 2017-12-29 | Novo Nordisk A/S | Urządzenie rejestrujące dawkę do urządzenia do podawania leku |
| US9163073B2 (en) | 2013-04-17 | 2015-10-20 | Amidebio, Llc | Chemically and thermodynamically stable insulin analogues and improved methods for their production |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| RS58039B1 (sr) | 2013-05-02 | 2019-02-28 | Novo Nordisk As | Oralno doziranje glp-1 jedinjenja |
| CA2926701A1 (en) | 2013-10-07 | 2015-04-16 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
| CA2932873A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| JP6641280B2 (ja) | 2014-01-09 | 2020-02-05 | サノフイＳａｎｏｆｉ | インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤 |
| KR20160104726A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형 |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| JP6737793B2 (ja) * | 2015-01-29 | 2020-08-12 | ノヴォ ノルディスク アー／エス | 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| UY36870A (es) * | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| JP7143275B2 (ja) | 2016-07-22 | 2022-09-28 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | インスリンアナログ |
| AU2017332408B2 (en) * | 2016-09-23 | 2022-02-10 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| CN109891237B (zh) * | 2016-10-24 | 2022-08-23 | 诺和诺德股份有限公司 | 胰岛素制剂的生物测定法 |
| ES2828526T3 (es) | 2016-11-07 | 2021-05-26 | Novo Nordisk As | Esteres activos DCHBS de compuestos PEG y sus usos |
| US11007144B2 (en) | 2016-11-15 | 2021-05-18 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| ES2886837T3 (es) | 2016-12-16 | 2021-12-21 | Novo Nordisk As | Composiciones farmacéuticas que contienen insulina |
| WO2018174668A2 (ko) | 2017-03-23 | 2018-09-27 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 |
| JP2020513019A (ja) | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー／エス | オリゴマー伸長インスリン−Ｆｃコンジュゲート |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| CA3071686A1 (en) | 2017-08-17 | 2019-02-21 | Novo Nordisk A/S | Novel acylated insulin analogues and uses thereof |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| KR102666154B1 (ko) | 2018-08-08 | 2024-05-20 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
| KR102646845B1 (ko) | 2018-08-08 | 2024-03-14 | 주식회사 대웅제약 | 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법 |
| EP3852873A1 (en) | 2018-09-19 | 2021-07-28 | Ziylo Ltd | Glucose sensitive insulins and uses thereof |
| US20210393745A1 (en) | 2018-10-10 | 2021-12-23 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates and their medical use |
| TW202039437A (zh) | 2018-12-11 | 2020-11-01 | 法商賽諾菲公司 | 肽黏合劑 |
| CN114096269B (zh) | 2019-07-12 | 2024-06-11 | 诺和诺德股份有限公司 | 高浓度胰岛素制剂 |
| KR20220112817A (ko) | 2019-12-10 | 2022-08-11 | 사노피 | 설폰아미드 및 폴리펩티드의 콘주게이트를 형성하는 방법 |
| WO2021231676A1 (en) | 2020-05-15 | 2021-11-18 | Eli Lilly And Company | Extended time action acylated insulin compounds |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| WO2023144240A1 (en) | 2022-01-26 | 2023-08-03 | Novo Nordisk Research Centre Oxford Limited | Glucose sensitive insulin derivatives and uses thereof |
| CN115716877B (zh) * | 2022-07-04 | 2023-09-01 | 北京惠之衡生物科技有限公司 | 一种表达glp-1和胰岛素缀合物多肽的重组工程菌 |
| WO2024194897A1 (en) * | 2023-03-22 | 2024-09-26 | Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) | A glycation resistant insulin polypeptide and a method of preparing the same thereof |
| CN120887973A (zh) * | 2024-06-13 | 2025-11-04 | 惠升生物制药股份有限公司 | 一种长效酰化胰岛素衍生物及其应用 |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2832685A (en) * | 1952-05-24 | 1958-04-29 | Crest Foods Co Inc | Solubilization of milk proteins |
| US3528960A (en) * | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3719655A (en) * | 1969-12-05 | 1973-03-06 | Lilly Co Eli | Process for the crystallization of the ammonium and alkali metal salts in insulin |
| US3950517A (en) * | 1970-05-08 | 1976-04-13 | National Research Development Corporation | Insulin derivatives |
| US3869437A (en) * | 1970-05-08 | 1975-03-04 | Nat Res Dev | Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4033941A (en) * | 1975-12-17 | 1977-07-05 | Eli Lilly And Company | Process for purifying glucagon |
| GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
| JPS5767548A (en) | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
| NZ199391A (en) | 1981-01-02 | 1985-12-13 | Genentech Inc | Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin |
| US4546082A (en) | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| PH23446A (en) | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
| DK463887D0 (da) | 1987-09-07 | 1987-09-07 | Novo Industri As | Gaerleader |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| DK257988D0 (da) * | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
| DK336188D0 (da) | 1988-06-20 | 1988-06-20 | Nordisk Gentofte | Propeptider |
| WO1990001038A1 (en) * | 1988-07-20 | 1990-02-08 | Nordisk Gentofte A/S | Human insulin analogs and preparations containing them |
| HUT56857A (en) | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
| US5716927A (en) * | 1988-12-23 | 1998-02-10 | Novo Nordisk A/S | Insulin analogs having a modified B-chain |
| DE3844211A1 (de) | 1988-12-29 | 1990-07-05 | Hoechst Ag | Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| DK105489D0 (da) | 1989-03-03 | 1989-03-03 | Novo Nordisk As | Polypeptid |
| IL93282A (en) | 1989-02-09 | 1995-08-31 | Lilly Co Eli | Insulin analogues |
| FI914898A0 (fi) | 1989-04-20 | 1991-10-17 | Sinai School Medicine | Leverspecifika insulinanaloger. |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| CA2027930C (en) * | 1989-10-19 | 1998-06-30 | Tsuyoshi Miyazaki | Polymer complexes of a sugar response type |
| US5179189A (en) * | 1990-01-19 | 1993-01-12 | Nova Pharmaceutical Corporation | Fatty acid terminated polyanhydrides |
| DK45590D0 (enExample) | 1990-02-21 | 1990-02-21 | Novo Nordisk As | |
| DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
| DK158390D0 (da) | 1990-07-02 | 1990-07-02 | Novo Nordisk As | Nye peptider |
| WO1992001476A1 (en) | 1990-07-26 | 1992-02-06 | University Of Iowa Research Foundation | Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule |
| DK10191D0 (da) | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
| US5336782A (en) | 1991-04-24 | 1994-08-09 | Kuraray Co., Ltd. | Long chain carboxylic acid imide ester |
| EP0952855B1 (en) * | 1991-07-03 | 2005-07-27 | Meditech Research Limited | Use of hyaluronan in gene therapy |
| TW224471B (enExample) * | 1991-11-26 | 1994-06-01 | Lilly Co Eli | |
| WO1994008599A1 (en) | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| NZ273285A (en) | 1993-09-17 | 1997-10-24 | Novo Nordisk As | Insulin derivatives and compositions thereof |
| US6869930B1 (en) * | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| GB9323588D0 (en) | 1993-11-16 | 1994-01-05 | Cortecs Ltd | Hydrophobic preparation |
| WO1995016708A1 (en) | 1993-12-17 | 1995-06-22 | Novo Nordisk A/S | Proinsulin-like compounds |
| DE69535897D1 (de) | 1994-03-07 | 2009-01-22 | Nektar Therapeutics | Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin |
| US5639642A (en) | 1994-06-16 | 1997-06-17 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
| ZA954983B (en) | 1994-06-17 | 1996-02-14 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5693609A (en) * | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| KR0150565B1 (ko) | 1995-02-15 | 1998-08-17 | 김정재 | 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법 |
| US6251856B1 (en) * | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| CA2215694A1 (en) | 1995-03-17 | 1996-09-26 | Novo Nordisk A/S | Insulin derivatives |
| IL118127A0 (en) | 1995-05-05 | 1996-09-12 | Lilly Co Eli | Single chain insulin with high bioactivity |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| US20030104981A1 (en) * | 1995-11-03 | 2003-06-05 | Jelena Mandic | Human insulin analogues |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| WO1998001473A1 (en) | 1996-07-05 | 1998-01-15 | Novo Nordisk A/S | Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides |
| ATE278711T1 (de) | 1996-07-11 | 2004-10-15 | Novo Nordisk As | Verfahren zur selektiven acetylierung |
| PT821006E (pt) * | 1996-07-26 | 2004-09-30 | Aventis Pharma Gmbh | Derivados de insulina com ligacao a zinco aumentada |
| WO1998032867A1 (en) | 1997-01-24 | 1998-07-30 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| US6310038B1 (en) | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
| PL195845B1 (pl) | 1997-10-24 | 2007-10-31 | Novo Nordisk As | Rozpuszczalny w wodzie agregat pochodnych insuliny |
| HUP0004169A3 (en) | 1997-10-24 | 2001-06-28 | Lilly Co Eli | Insoluble insulin compositions and process for production thereof |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| CA2309955A1 (en) | 1997-11-12 | 1999-05-20 | Alza Corporation | Method for decreasing self-association of polypeptides |
| CO4970787A1 (es) | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| CA2334859A1 (en) | 1998-06-12 | 1999-12-23 | Kings College London | Insulin analogue |
| GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
| CA2341624C (en) | 1998-08-25 | 2008-12-02 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| TW570805B (en) | 1998-09-01 | 2004-01-11 | Hoffmann La Roche | Water-soluble pharmaceutical composition in an ionic complex |
| US7030083B2 (en) * | 1998-09-09 | 2006-04-18 | University Of Washington | Treatment of eclampsia and preeclampsia |
| CN1210058C (zh) | 1998-10-16 | 2005-07-13 | 诺沃挪第克公司 | 用于肺送递的稳定的浓缩胰岛素制剂 |
| US6660715B2 (en) * | 1998-11-19 | 2003-12-09 | Massachusetts Institute Of Technology | Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery |
| JP2002535287A (ja) | 1999-01-26 | 2002-10-22 | イーライ・リリー・アンド・カンパニー | 単分散性６量体のアシル化されたインスリンアナログ製剤 |
| WO2000061178A1 (en) | 1999-04-13 | 2000-10-19 | Inhale Therapeutics Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| JP2002543092A (ja) | 1999-04-27 | 2002-12-17 | イーライ・リリー・アンド・カンパニー | 肺投与用インスリン結晶 |
| CA2372393A1 (en) | 1999-05-19 | 2000-11-23 | Bassil I. Dahiyat | Novel proteins with insulin-like activity useful in the treatment of diabetes |
| US6746853B1 (en) * | 1999-05-19 | 2004-06-08 | Xencor, Inc. | Proteins with insulin-like activity useful in the treatment of diabetes |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| CN1141974C (zh) * | 2000-06-07 | 2004-03-17 | 张昊 | 结肠定位释放的口服生物制剂 |
| US6867183B2 (en) | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| CN1160122C (zh) * | 2001-04-20 | 2004-08-04 | 清华大学 | 一种制备口服胰岛素油相制剂的方法 |
| KR20030097876A (ko) | 2001-05-21 | 2003-12-31 | 넥타르 테라퓨틱스 | 화학적으로 개질된 인슐린의 폐 투여 |
| US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| WO2003013573A1 (en) | 2001-08-10 | 2003-02-20 | Epix Medical, Inc. | Polypeptide conjugates with extended circulating half-lives |
| US7030082B2 (en) | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
| UY27439A1 (es) | 2001-09-07 | 2003-04-30 | Nobex Corp | Procedimiento para sintetizar un conjunto de oligomero-polipeptido insulina, conjugado oligomero-polipeptido de proinsulina, composicion de conjugado oligomero-insulina, procedimiento para sintetizar un conjugado oligomero-polipeptido c-peptido, conj |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| EP1453860A2 (en) | 2001-12-02 | 2004-09-08 | Novo Nordisk A/S | Novel glucose-dependant insulins |
| EP1460992B1 (en) | 2001-12-03 | 2009-03-11 | Dor Biopharma, Inc. | Stabilized reverse micelle compositions and uses thereof |
| AU2002314790A1 (en) * | 2001-12-05 | 2003-06-23 | Dow Global Technologies Inc. | Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications |
| AU2002346490A1 (en) | 2001-12-20 | 2003-07-09 | Eli Lilly And Company | Insulin molecule having protracted time action |
| AU2003218635A1 (en) | 2002-05-07 | 2003-11-11 | Novo Nordisk A/S | Soluble formulations comprising insulin aspart and insulin detemir |
| WO2003094956A1 (en) | 2002-05-07 | 2003-11-20 | Novo Nordisk A/S | Soluble formulations comprising monomeric insulin and acylated insulin |
| WO2003105768A2 (en) * | 2002-06-13 | 2003-12-24 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
| CN1165549C (zh) | 2002-06-15 | 2004-09-08 | 江苏万邦生化医药股份有限公司 | 胰岛素的纯化方法 |
| EP1633391B1 (en) | 2003-06-03 | 2011-10-19 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
| EP1644411A2 (en) | 2003-07-11 | 2006-04-12 | Novo Nordisk A/S | Stabilised insulin compositions |
| SI1648933T1 (sl) | 2003-07-25 | 2010-01-29 | Conjuchem Biotechnologies Inc | Dolgo delujoäś inzulinski derivat in metoda zanj |
| AU2004261353B2 (en) | 2003-08-05 | 2009-12-10 | Novo Nordisk A/S | Novel insulin derivatives |
| KR101152470B1 (ko) | 2003-08-13 | 2012-06-01 | 바이오콘 리미티드 | 치료제용 마이크로-입자 지방산 염 고형 투약 제형 |
| EP1687428A1 (en) | 2003-11-14 | 2006-08-09 | Novo Nordisk A/S | Processes for making acylated insulin |
| KR101243648B1 (ko) | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제 |
| US7371381B2 (en) | 2003-12-12 | 2008-05-13 | Amgen Inc. | Anti-galanin antibodies and uses thereof |
| DE10358387A1 (de) | 2003-12-13 | 2005-07-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung |
| WO2005092301A1 (en) | 2004-03-26 | 2005-10-06 | Universita' Degli Studi Di Parma | Insulin highly respirable microparticles |
| US7244709B2 (en) * | 2004-05-10 | 2007-07-17 | Nastech Pharamecutical Company Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| CN101027318B (zh) * | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物，制剂及其用途 |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| CA2587601C (en) * | 2004-12-03 | 2017-11-07 | Rhode Island Hospital | Diagnosis and treatment of alzheimer's disease |
| US20090036353A1 (en) | 2005-01-27 | 2009-02-05 | Novo Nordisk A/S | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers |
| WO2006082204A1 (en) | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
| ES2435522T3 (es) | 2005-02-02 | 2013-12-20 | Novo Nordisk A/S | Derivados de insulina |
| EP1863840A1 (en) | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Pegylated single-chain insulin |
| WO2007006320A1 (en) | 2005-07-12 | 2007-01-18 | Sherine Hassan Abbas Helmy | Drinkable oral insulin liquid and capsules |
| US20070086952A1 (en) | 2005-09-29 | 2007-04-19 | Biodel, Inc. | Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
| WO2007047948A2 (en) | 2005-10-20 | 2007-04-26 | Nastech Pharmaceutical Company Inc. | Intranasal administration of rapid acting insulin |
| EP1969004B1 (en) | 2005-12-28 | 2011-08-10 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
| WO2007096332A1 (en) | 2006-02-21 | 2007-08-30 | Novo Nordisk A/S | Single-chain insulin analogues and pharmaceutical formulations thereof |
| JP5202338B2 (ja) | 2006-02-27 | 2013-06-05 | ノボ・ノルデイスク・エー／エス | 新規インシュリン誘導体 |
| WO2007104737A1 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| AU2007247109B2 (en) | 2006-05-09 | 2012-03-15 | Novo Nordisk A/S | Insulin derivative |
| WO2007128815A1 (en) | 2006-05-09 | 2007-11-15 | Novo Nordisk A/S | Insulin derivative |
| CN101573133B (zh) * | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | Peg化延长的胰岛素 |
| CN101541830A (zh) | 2006-09-22 | 2009-09-23 | 诺沃-诺迪斯克有限公司 | 蛋白酶抗性的胰岛素类似物 |
| JP2010525033A (ja) | 2007-04-30 | 2010-07-22 | ノボ・ノルデイスク・エー／エス | 高濃縮のインスリン溶液及び組成物 |
| AU2008257505B2 (en) | 2007-06-01 | 2013-05-16 | Novo Nordisk A/S | Stable non-aqueous pharmaceutical compositions |
| EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| EP2170945A1 (en) | 2007-07-16 | 2010-04-07 | Novo Nordisk A/S | Protease stabilized, pegylated insulin analogues |
| EP2017288A1 (en) | 2007-07-16 | 2009-01-21 | Novo Nordisk A/S | Protease stabilized, pegylated insulin analogues |
| AU2008288413B2 (en) | 2007-08-15 | 2013-09-26 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| WO2009022006A1 (en) | 2007-08-15 | 2009-02-19 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| CN101970477B (zh) | 2008-03-14 | 2014-12-31 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定的胰岛素类似物 |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
-
2007
- 2007-09-20 CN CNA2007800431301A patent/CN101541830A/zh active Pending
- 2007-09-20 KR KR1020157005461A patent/KR101729986B1/ko not_active Expired - Fee Related
- 2007-09-20 HU HUE07820423A patent/HUE029512T2/en unknown
- 2007-09-20 KR KR1020097005790A patent/KR101699370B1/ko not_active Expired - Fee Related
- 2007-09-20 AU AU2007298919A patent/AU2007298919C1/en not_active Ceased
- 2007-09-20 PL PL07820423T patent/PL2074141T3/pl unknown
- 2007-09-20 ES ES07820423.7T patent/ES2601839T3/es active Active
- 2007-09-20 RU RU2009114324/10A patent/RU2524150C2/ru not_active IP Right Cessation
- 2007-09-20 CA CA002663074A patent/CA2663074A1/en not_active Withdrawn
- 2007-09-20 MX MX2009002999A patent/MX2009002999A/es active IP Right Grant
- 2007-09-20 DK DK07820423.7T patent/DK2074141T3/en active
- 2007-09-20 BR BRPI0717098A patent/BRPI0717098B8/pt not_active IP Right Cessation
- 2007-09-20 PT PT78204237T patent/PT2074141T/pt unknown
- 2007-09-20 WO PCT/EP2007/059990 patent/WO2008034881A1/en not_active Ceased
- 2007-09-20 US US12/442,190 patent/US9018161B2/en active Active
- 2007-09-20 JP JP2009528727A patent/JP5864834B2/ja active Active
- 2007-09-20 EP EP11173251A patent/EP2404934A1/en not_active Withdrawn
- 2007-09-20 EP EP07820423.7A patent/EP2074141B1/en not_active Revoked
- 2007-09-21 TW TW096135252A patent/TW200829600A/zh unknown
-
2009
- 2009-03-16 IL IL197609A patent/IL197609A/en active IP Right Grant
- 2009-03-16 ZA ZA2009/01838A patent/ZA200901838B/en unknown
- 2009-04-20 NO NO20091563A patent/NO20091563L/no not_active Application Discontinuation
-
2014
- 2014-01-24 JP JP2014011829A patent/JP2014129355A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2524150C2 (ru) | 2014-07-27 |
| US9018161B2 (en) | 2015-04-28 |
| US20100009898A1 (en) | 2010-01-14 |
| JP2014129355A (ja) | 2014-07-10 |
| RU2009114324A (ru) | 2010-10-27 |
| AU2007298919A1 (en) | 2008-03-27 |
| IL197609A (en) | 2017-04-30 |
| KR101699370B1 (ko) | 2017-02-14 |
| TW200829600A (en) | 2008-07-16 |
| WO2008034881A1 (en) | 2008-03-27 |
| DK2074141T3 (en) | 2016-11-28 |
| ZA200901838B (en) | 2010-02-24 |
| KR101729986B1 (ko) | 2017-04-25 |
| KR20150031494A (ko) | 2015-03-24 |
| NO20091563L (no) | 2009-04-20 |
| BRPI0717098B1 (pt) | 2018-08-07 |
| HUE029512T2 (en) | 2017-03-28 |
| IL197609A0 (en) | 2011-08-01 |
| KR20090071561A (ko) | 2009-07-01 |
| EP2074141B1 (en) | 2016-08-10 |
| PT2074141T (pt) | 2016-11-10 |
| MX2009002999A (es) | 2009-04-01 |
| JP2010504087A (ja) | 2010-02-12 |
| PL2074141T3 (pl) | 2017-02-28 |
| AU2007298919C1 (en) | 2014-02-06 |
| EP2404934A1 (en) | 2012-01-11 |
| JP5864834B2 (ja) | 2016-02-17 |
| BRPI0717098A2 (pt) | 2013-10-08 |
| CA2663074A1 (en) | 2008-03-27 |
| ES2601839T3 (es) | 2017-02-16 |
| EP2074141A1 (en) | 2009-07-01 |
| CN101541830A (zh) | 2009-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009002999A (es) | Analogos de insulina resistentes a proteasa. | |
| BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
| KR102677852B1 (ko) | 글루코스 조절된 구조 전환을 포함하는 인슐린 유사체 | |
| BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
| BR0210711A (pt) | Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto | |
| BR0317458A (pt) | EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| BRPI0409916A (pt) | ácidos carboxìlicos substituìdos com fenila | |
| BRPI0409447A (pt) | ácidos fenilalcanóicos substituìdos | |
| BR0214986A (pt) | S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| BRPI0910461B8 (pt) | hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso | |
| BRPI0408490A (pt) | composições que compreendem ácidos graxos e aminoácidos | |
| BRPI0416796A (pt) | compostos orgánicos | |
| BRPI0820622A2 (pt) | Compostos derivados de aminotiazol, processo para a sua preparação, composição farmacêutica que os compreende, uso dos mesmos e métodos para o tratamento e/ou profilaxia de diabetes e outras enfermidades | |
| BRPI0915592A2 (pt) | composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii | |
| BR0214553A (pt) | Compostos, processo de preparação, em fase lìquida, dos compostos, e, composições farmacêuticas | |
| BRPI0606930A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente | |
| BRPI0820203A2 (pt) | Compostos de pirrdina, processo para a sua preparação, composição farmacêutica que os compreende, uso de composto e método para o tratamento e/ou profilaxia de diabetes mellitus do tipo ii e outras enfermidades | |
| BR112021016782A2 (pt) | Composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica | |
| BRPI0511703A (pt) | composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o inìcio do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, sìndrome x, um distúrbio lipìdico, aterosclerose, e uma condição | |
| BRPI0612104A8 (pt) | composto, mistura diastereomérica, composição farmacêutica, e, método para tratar infecções por hepatite c em um paciente e para tratar infecções por hcv em um paciente | |
| BRPI0411484A (pt) | composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica | |
| BRPI0715853B8 (pt) | uso de polióis contendo pelo menos dois grupos hidróxi para estabilizar formas polimorfas da rifaximina, rifaximina beta, suas preparações medicinais, seus microgrânulos e seu processo de preparação | |
| BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
| BRPI0713755A8 (pt) | composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo | |
| BRPI0609278B8 (pt) | método para preparar uma composição farmacêutica e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2793 DE 16-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |